HomeCompareBTTX vs NOBL

BTTX vs NOBL: Dividend Comparison 2026

BTTX yields 2000000.00% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTTX wins by $4.879226400974806e+39M in total portfolio value
10 years
BTTX
BTTX
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full BTTX calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — BTTX vs NOBL

📍 BTTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBTTXNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BTTX + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BTTX pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BTTX
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, BTTX beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BTTX + NOBL for your $10,000?

BTTX: 50%NOBL: 50%
100% NOBL50/50100% BTTX
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTTX right now

BTTX
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-27.3
Piotroski
2/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BTTX buys
0
NOBL buys
0
No recent congressional trades found for BTTX or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBTTXNOBL
Forward yield2000000.00%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.879226400974806e+39M$22.9K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$249.78
Total dividends collected$4.879195005460081e+39M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BTTX vs NOBL ($10,000, DRIP)

YearBTTX PortfolioBTTX Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,917$217.08+$200.00MBTTX
2$3,738,731,768,458$3,738,517,757,009.35$11,903$221.48+$3738731.76MBTTX
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,962$225.68+$65315062866.92MBTTX
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$14,099$229.68+$1066400830062625.00MBTTX
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$15,319$233.49+$16272182796453826560.00MBTTX
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$16,628$237.10+$2.3205424011366188e+23MBTTX
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$18,033$240.53+$3.0927990661046884e+27MBTTX
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$19,539$243.78+$3.8524105697352695e+31MBTTX
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$21,154$246.86+$4.484688260147987e+35MBTTX
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$22,884$249.78+$4.879226400974806e+39MBTTX

BTTX vs NOBL: Complete Analysis 2026

BTTXStock

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Full BTTX Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this BTTX vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BTTX vs SCHDBTTX vs JEPIBTTX vs OBTTX vs KOBTTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.